HealthInvest showcased ASX-listed healthcare companies where scientific innovation, commercial opportunity and patient outcomes align.
Program aims to improve diagnosis, support disease management and help people living with focal segmental glomerulosclerosis (FSGS) better understand available treatment optionsROCKVILLE, Md., June 09 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results